Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 6.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1999 to 2008

Recipients with Pancreas Transplant Alone (PTA) Transplants

  Year of Transplant
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Transplants 139 134 168 180 160 183 199 174 210 223
Tx with Antirejection Treatments 30 28 20 36 31 34 31 23 37 40
Antibodies Any in Category 90.0% 92.9% 65.0% 63.9% 77.4% 55.9% 51.6% 39.1% 54.1% 57.5%
Atgam/NRATG/NRATS 0.0% 0.0% 5.0% 0.0% 0.0% 2.9% 0.0% 0.0% 0.0% 2.5%
OKT3 73.3% 57.1% 30.0% 38.9% 25.8% 20.6% 25.8% 21.7% 16.2% 22.5%
Thymoglobulin 40.0% 57.1% 40.0% 36.1% 54.8% 26.5% 35.5% 13.0% 40.5% 32.5%
Zenapax 13.3% 3.6% 5.0% 2.8% 9.7% 2.9% 0.0% 4.3% 2.7% 2.5%
Simulect 3.3% 3.6% 5.0% 0.0% 0.0% 0.0% 0.0% 4.3% 0.0% 0.0%
Campath 0.0% 0.0% 0.0% 11.1% 38.7% 26.5% 3.2% 0.0% 0.0% 2.5%
Corticosteroids Any in Category 73.3% 78.6% 90.0% 86.1% 80.6% 85.3% 83.9% 95.7% 94.6% 85.0%
Steroids 73.3% 78.6% 90.0% 86.1% 80.6% 85.3% 83.9% 95.7% 94.6% 85.0%
Antimetabolites Any in Category 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Methotrexate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of October 1, 2010.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.